23andMe, once a standout in direct-to-consumer genetic testing, has seen its momentum fade and market value fall sharply. Its setback highlights tough commercialization hurdles—costs, competition, and sustained demand—that could influence how India’s genetic-testing market grows. Yet the disruption may also open room for smarter, locally aligned offerings and stronger partnerships across healthcare.
India’s pharmaceutical exports fell 23.17% in March, a sharp reversal attributed to the West Asia conflict disrupting both shipping routes and air transit hubs. With Dubai and Abu Dhabi impacted, freight costs rose and losses are estimated at ₹2,500–₹5,000 crore. The hit threatens the smooth flow of essential medicines to global markets despite earlier FY26 growth.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
